temozolomide has been researched along with hydroxychloroquine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Gallagher, M; Heitjan, DF; Kaiser, J; Kramer, A; Leone, R; Nathanson, KL; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rangwala, R; Rodgers, G; Schuchter, LM; Tan, KS; Troxel, AB | 1 |
| Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X | 1 |
| Adamski, V; Adelung, R; Ceynowa, F; Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Balachandar, A; Bhagirath, E; Pandey, S; Vegh, C; Wear, D | 1 |
2 review(s) available for temozolomide and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
2 trial(s) available for temozolomide and hydroxychloroquine
| Article | Year |
|---|---|
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Temozolomide; Treatment Outcome | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Demography; Female; Glioblastoma; Humans; Hydroxychloroquine; Male; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2014 |
3 other study(ies) available for temozolomide and hydroxychloroquine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Drug Administration Schedule; Drug Synergism; Glioblastoma; Gossypol; Humans; Hydroxychloroquine; Temozolomide | 2018 |
Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Child; Cisplatin; Glioblastoma; Humans; Hydroxychloroquine; Infant; Neuroblastoma; Temozolomide | 2023 |